TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11139311

Group type: EXPERIMENTAL
Intervention: Oral paclitaxel (120 mg/m²) with GF120918 (1000 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral paclitaxel (120 mg/m²) with CsA (previous study)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous paclitaxel (175 mg/m²)
Number of subjects: 6
Study: 9596394

Group type: EXPERIMENTAL
Intervention: Injection of 100 BTA U into the tibialis posterior muscle, followed by ankle-foot taping (group B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Injection of 190 to 320 BTA U into several calf muscles (group A)
Number of subjects: 18
Study: 7889428

Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate Aqueous Nasal Spray (FPANS) 200 micrograms once daily
Number of subjects: 214

Group type: COMPARATOR
Intervention: Terfenadine tablets (60 mg) twice daily
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 3498406

Group type: EXPERIMENTAL
Intervention: 1.5 mg . kg‐1 propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 mg . kg‐1 methohexitone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg . kg‐1 with fentanyl 1.5 micrograms . kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 2 micrograms . kg‐1 with vecuronium 0.1 mg . kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methohexitone 2 mg . kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol and methohexitone
Number of subjects: 60
Study: 29518468

Group type: EXPERIMENTAL
Intervention: Nutrients highly related to nutritional quality highlighted using a front‐of‐package (FOP) label
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrients unrelated to nutritional quality highlighted using a front‐of‐package (FOP) label
Number of subjects: 0

Group type: COMPARATOR
Intervention: No nutritional information highlighted
Number of subjects: 0
Study: 28651642

Group type: EXPERIMENTAL
Intervention: si guan xue plus commonly used acupoints arm (n=14)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: si guan xue arm (n=14)
Number of subjects: 42

Group type: COMPARATOR
Intervention: commonly used acupoints arm (n=14)
Number of subjects: 42
Study: 26163088

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 754
Study: 23769959

Group type: EXPERIMENTAL
Intervention: Stress (SECPT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study: 21688915

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 66

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 66
Study: 19549706

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Interferon-alpha (9 million units s.c. injection three times/week)
Number of subjects: 304
Study: 16512083

Group type: EXPERIMENTAL
Intervention: Explicit, systematic reading intervention in Spanish for treatment group (daily for 50 min)
Number of subjects: 69
Study: 12649125

Group type: EXPERIMENTAL
Intervention: Standard therapy plus recombinant surfactant protein C surfactant (Venticute) given four times over 24 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 11460286

Group type: EXPERIMENTAL
Intervention: Resin-based sealant (Delton)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (Fuji III)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Dentist with chairside assistance (both sealants)
Number of subjects: 140
Study: 8671224

Group type: EXPERIMENTAL
Intervention: Oestrogen for 12 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oestrogen and Crinone (vaginal progesterone) for another 12 days
Number of subjects: 20
Study: 1418078

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isoniazid plus rifampicin (RMP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study: 6549147

Group type: EXPERIMENTAL
Intervention: CMF (Cyclophosphamide, Methotrexate, and Fluorouracil)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CMF (Cyclophosphamide, Methotrexate, and Fluorouracil) plus tamoxifen
Number of subjects: 49
Study: 31609787

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 30 U
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 50 U
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 30883859

Group type: EXPERIMENTAL
Intervention: Monitoring frequency decreased at a CD4 threshold of 350 cells/μl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment switched at an HIV-RNA threshold of 1000 copies/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No direct effect assumption
Number of subjects: 0
Study: 29278315

Group type: EXPERIMENTAL
Intervention: Menatetrenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 26772449

Group type: EXPERIMENTAL
Intervention: Vitamin A and zinc combined supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily zinc supplement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined vitamin A-zinc supplement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin A every 2 months
Number of subjects: 0
Study: 23978948

Group type: EXPERIMENTAL
Intervention: Fentanyl 3 μg/ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ropivacaine 0.1%
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 60
Study: 22882515

Group type: EXPERIMENTAL
Intervention: Selective resection of dorsal nerve (SRDN)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Circumcision only (Control)
Number of subjects: 101
Study: 19225354

Group type: EXPERIMENTAL
Intervention: travoprost 0.004% eye drops
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (normal eyes)
Number of subjects: 37
Study: 17472485

Group type: EXPERIMENTAL
Intervention: 300 mg/1.2 g NT-GA combination
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 600 mg/2.4 g NT-GA combination
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 15183553

Group type: EXPERIMENTAL
Intervention: Distance-learning programme (educational package for the GP and a patient information leaflet)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Written guidelines on LUTS mailed to the GP (Control)
Number of subjects: 151
Study: 12575373

Group type: EXPERIMENTAL
Intervention: Fluticasone inhalation combined with Jinacon (JNC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluticasone inhalation alone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: JNC alone
Number of subjects: 72
Study: 9649143

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg day(-1)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 7843478

Group type: EXPERIMENTAL
Intervention: Forceps
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Ventouse
Number of subjects: 508
Study: 2656777

Group type: EXPERIMENTAL
Intervention: Tonazocine mesylate 4 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tonazocine mesylate 8 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 10 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 1080959

Group type: EXPERIMENTAL
Intervention: Pharmacologic doses of steroids administered early in the shock state (within the first hour) for periods of less than forty-eight hours
Number of subjects: 0
Study: 31122129

Group type: EXPERIMENTAL
Intervention: English speakers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spanish speakers
Number of subjects: 0
Study: 31694845

Group type: EXPERIMENTAL
Intervention: VHA-guided management of bleeding
Number of subjects: 1000
Study: 28359172

Group type: EXPERIMENTAL
Intervention: NIPARA device
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (oral airway only)
Number of subjects: 37
Study: 25933111

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/day)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Cisplatin/Gemcitabine (up to six cycles; cisplatin 75 mg/m2 [d1]; gemcitabine 1000 mg/m2 [d1,8])
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 364
Study: 23714411

Group type: EXPERIMENTAL
Intervention: Mums Step it Up Program
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Pedometer only
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study: 21742485

Group type: EXPERIMENTAL
Intervention: Irinotecan 250mg/m² q3w (first cycle) increased to 350mg/m² depending on toxicity
Number of subjects: 40

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Irinotecan
Number of subjects: 40
Study: 19421851

Group type: EXPERIMENTAL
Intervention: Noncontingent monetary incentives ($1, $2, $5, mood magnet)
Number of subjects: 500

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 500
Study: 16009445

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day followed by Fenofibrate 200 mg/day for an additional 12 weeks
Number of subjects: 40
Study: 14959471

Group type: EXPERIMENTAL
Intervention: Standard drugs plus bicycle exercise (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard drugs only (group 2)
Number of subjects: 100
Study: 10849577

Group type: EXPERIMENTAL
Intervention: Continuous exercise at 60-75% of maximum aerobic capacity, 3 days per week, 30 min per session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent exercise using brisk walking for two, 15 min sessions, 5 days per week
Number of subjects: 0
Study: 9322328

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 323

Group type: COMPARATOR
Intervention: Physiotherapy treatment
Number of subjects: 323
Study: 8442964

Group type: EXPERIMENTAL
Intervention: IV ondansetron (two 8 mg doses 8 hours apart)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 3536525

Group type: EXPERIMENTAL
Intervention: Intracavitary talc
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intracavitary tetracycline
Number of subjects: 41
Study: 30782675

Group type: EXPERIMENTAL
Intervention: Medical skin camouflage (MSC) intervention for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control (no MSC during study period)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Qualitative interviews and focus groups with prison staff and women prisoners
Number of subjects: 40
Study: 30005647

Group type: EXPERIMENTAL
Intervention: Road safety bus stickers in minibuses
Number of subjects: 2410

Group type: EXPERIMENTAL
Intervention: Road safety bus stickers in big buses
Number of subjects: 2410
Study: 26947212

Group type: COMPARATOR
Intervention: Enhanced care (family physician notification and follow-up)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Collaborative care
Number of subjects: 227
Study: 25526794

Group type: EXPERIMENTAL
Intervention: Digital multiuse breathalyser
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Single-use breathalyser 1
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Single-use breathalyser 2
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Self-reported alcohol consumption threshold of 5 UK units or fewer
Number of subjects: 208
Study: 22101394

Group type: EXPERIMENTAL
Intervention: D-cycloserine (125 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Exposure/Response Prevention (Exp/RP)
Number of subjects: 32
Study: 20850097

Group type: EXPERIMENTAL
Intervention: SeptRx PFO closure device
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg and Clopidogrel 75 mg for 6 months
Number of subjects: 13
Study: 18046991

Group type: EXPERIMENTAL
Intervention: Quality of life (QOL) questionnaire for patients with type II diabetes
Number of subjects: 126
Study: 12600252

Group type: EXPERIMENTAL
Intervention: Rapid release with Air Viva 2 circuit
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rapid release with Mapleson-C circuit
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rapid release with Mapleson-F circuit
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Larger volume delivery
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lower target volume with Mapleson circuits and rapid release
Number of subjects: 15

Group type: COMPARATOR
Intervention: Air Viva 2 circuit without rapid release
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mapleson-C circuit without rapid release
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mapleson-F circuit without rapid release
Number of subjects: 15
Study: 10705425

Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine around the sheath site
Number of subjects: 130

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 130
Study: 9373656

Group type: EXPERIMENTAL
Intervention: 3 days treatment with Quinimax® (10 mg/kg twice daily)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 5 days treatment with Quinimax® (10 mg/kg twice daily)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 7 days treatment with Quinimax® (10 mg/kg twice daily)
Number of subjects: 145
Study: 7839883

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (multivite group)
Number of subjects: 0
Study: 3755702

Group type: EXPERIMENTAL
Intervention: Partial meniscectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Total meniscectomy
Number of subjects: 200
Study: 31978060

Group type: EXPERIMENTAL
Intervention: Molecular xenomonitoring (MX) survey
Number of subjects: 9804

Group type: COMPARATOR
Intervention: Transmission Assessment Survey (TAS)
Number of subjects: 9804

Group type: COMPARATOR
Intervention: Microfilaria (Mf) survey
Number of subjects: 9804

Group type: EXPERIMENTAL
Intervention: Cost comparison of TAS and MX
Number of subjects: 9804
Study: 29544928

Group type: EXPERIMENTAL
Intervention: Residual congestion (CCS ≥ 3) at day 7 or discharge
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: Diuretic response
Number of subjects: 1572
Study: 26615475

Group type: EXPERIMENTAL
Intervention: Video (VI) group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: External Focus (EF) group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Internal Focus (IF) group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (CTRL) group
Number of subjects: 40
Study: 24189454

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 23050526

Group type: EXPERIMENTAL
Intervention: Policy implementation (discontinuation of additional payments for preventable infections)
Number of subjects: 398
Study: 20033629

Group type: EXPERIMENTAL
Intervention: Self-regulation intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 101
Study: 18511530

Group type: EXPERIMENTAL
Intervention: Intraarticular corticosteroid (1 mL, 40 mg methylprednisolone acetate) followed by a 12‐week comprehensive home exercise programme
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intraarticular serum physiologic (1 mL solution of 0.9% sodium chloride) followed by a 12‐week comprehensive home exercise programme
Number of subjects: 80
Study: 15818711

Group type: EXPERIMENTAL
Intervention: dsDNA‐based bioconjugate (abetimus sodium; LJP 394)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 12861145

Group type: EXPERIMENTAL
Intervention: Patient Global Impression of Severity
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Patient Global Impression of Improvement
Number of subjects: 1133
Study: 9890616

Group type: EXPERIMENTAL
Intervention: Dual energy x-ray absorptiometry (DXA)
Number of subjects: 45
Study: 9049962

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (CCG-1800 series, 1989-1994)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Moderate intensity chemotherapy (CCG-100 series, 1983-1989)
Number of subjects: 730
Study: 1802206

Group type: EXPERIMENTAL
Intervention: BHGH (0.25 IU.kg-1.day-1) with surgery and TPN
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BHGH (0.25 IU.kg-1.day-1) with TPN
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (TPN only)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BHGH (0.25 IU.kg-1.day-1)
Number of subjects: 30
Study: 6129091

Group type: EXPERIMENTAL
Intervention: Pafenolol (5 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pafenolol (7.5 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Terbutaline (inhaled in increasing doses)
Number of subjects: 7
Study: 30871431

Group type: EXPERIMENTAL
Intervention: Qualitative methods used in RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative RCT approaches (adaptive designs, pragmatic trials, realist RCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus on structural inequalities
Number of subjects: 0
Study: 28454809

Group type: EXPERIMENTAL
Intervention: Daytime presentation
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Nighttime presentation
Number of subjects: 1161
Study: 26475845

Group type: EXPERIMENTAL
Intervention: Biocompatible dialysis fluid (low in glucose degradation products)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard dialysis fluids
Number of subjects: 18
Study: 24332587

Group type: EXPERIMENTAL
Intervention: Supraperiosteal injection of methylprednisolone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral tablets of methylprednisolone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) injection of methylprednisolone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no steroids)
Number of subjects: 44
Study: 21947409

Group type: EXPERIMENTAL
Intervention: Backpack weighing 15 kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Backpack weighing 25 kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Backpack weighing 35 kg
Number of subjects: 7

Group type: COMPARATOR
Intervention: No backpack (NP)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Un-weighted backpack (NW)
Number of subjects: 7
Study: 19211720

Group type: EXPERIMENTAL
Intervention: 3 kcal/min lipid (L3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 kcal/min lipid and 1 kcal/min maltodextrin (L2/CHO1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 kcal/min lipid and 2 kcal/min maltodextrin (L1/CHO2)
Number of subjects: 10
Study: 17308271

Group type: EXPERIMENTAL
Intervention: DN-101 (45 microg orally 1 day before docetaxel)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: DN-101
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 12532367

Group type: EXPERIMENTAL
Intervention: Nurse-designed discharge-planning project (intervention)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 283
Study: 11093967

Group type: EXPERIMENTAL
Intervention: Red wine (60 g ethanol) with a standard dinner
Number of subjects: 0
Study: 8899140

Group type: EXPERIMENTAL
Intervention: Rape Supportive Cognitions (RSC) intervention
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Victim Empathy/Outcome Expectancies (VE/OE) intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 74
Study: 1815002

Group type: EXPERIMENTAL
Intervention: +0.50 D x 090
Number of subjects: 8

Group type: COMPARATOR
Intervention: +0.12 DS
Number of subjects: 8
Study: 6356605

Group type: COMPARATOR
Intervention: Verbascan (10 mg three times daily)
Number of subjects: 50
Study: 31995686

Group type: EXPERIMENTAL
Intervention: Interventional management
Number of subjects: 316

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Interventional management (sensitivity analysis)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Conservative management (sensitivity analysis)
Number of subjects: 316
Study: 30649492

Group type: EXPERIMENTAL
Intervention: Manual traction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Touch
Number of subjects: 20
Study: 28573777

Group type: EXPERIMENTAL
Intervention: PF‐05231023
Number of subjects: 107
Study: 25669832

Group type: EXPERIMENTAL
Intervention: Concurrent regimen with gefitinib (250 mg) and carboplatin/pemetrexed (AUC = 6 and 500 mg/m2; 3-weekly)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed (AUC = 6 and 500 mg/m2; 3-weekly)
Number of subjects: 80
Study: 22691724

Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 54

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 54
Study: 21811060

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (120 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pomegranate juice vs Placebo
Number of subjects: 20
Study: 19549035

Group type: EXPERIMENTAL
Intervention: Conventional radiofrequency (RF) ablation catheter (CRF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Irrigated RF tip catheter (IRF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cryoballoon catheter (CB)
Number of subjects: 30
Study: 16796705

Group type: EXPERIMENTAL
Intervention: Levodopa (100 mg single dose)
Number of subjects: 12
Study: 17301436

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (8-week program)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 36
Study: 10321615

Group type: EXPERIMENTAL
Intervention: Pro-Q aerosol foam skin protectant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20